The Europe molecular quality controls market is expected to reach US$ 109.59 million by 2028 from US$ 55.76 million in 2021; it is estimated to grow at a CAGR of 10.1% from 2021 to 2028.
Factors such as growing funds for genomics, declining cost of sequencing procedures, and increasing prevalence of genetic diseases fuel the growth of the market. However, the dearth of skilled professionals hinders the market growth.
Genome sequencing has now become one of the common techniques in clinical practices.As per the study ‘Integrating Genomics into Healthcare’, over the next a few years, the healthcare sector is expected to generate genomic data of over 60 million patients.
The growing implementation of genomic sequencing in healthcare systems is supported by substantial government investments, totaling over US$ 4 billion by at least 14 countries.The UK announced world’s largest genome project as a part of 200 million public–private collaboration between charitable organizations and pharmaceutical companies.
Led by Innovate UK, a part of UK Research and Innovation, the project was initiated to support researchers and industries through funds to combine data and real-world evidence obtained from health services in the UK as well as to create new products and services for more efficient and early disease diagnosis.Such continuous funding by the manufacturers and governments in the field of genomics is supporting the growth of the molecular quality controls market.
Also, the cost of genome sequencing, as well as next-generation sequencing, has dropped radically in the past 6–7 years. Moreover, the process requires a lesser number of days for completion. Lowering costs and accelerating overall process enable service providers to secure larger profit margins, along with helping them expand their clientele. Thus, the lowered cost of genome sequencing is propelling the number of molecular biology procedures carried out for different purpose, thereby driving the use of molecular quality controls.
The European region is highly affected by the outbreak of the COVID-19 pandemic.The European economy is severely affected due to the exponential growth of COVID-19 cases in the region.
Molecular quality controls is a used in the process for R&D.The rising numbers of product launches in 2020 and rising incidence of COVID-19 has positive impacted in the Europe molecular quality controls market.
For instance, UK based Launch Diagnostics introduced AmpliRun and AmpliRun total coronavirus molecular controls for in vitro diagnostic techniques based on nucleic acid amplification. AmpliRun Total is used for external quality control for nucleic acids detection in Europe.
The Europe molecular quality controls market, by product, is segmented into independent controls and instrument specific controls. The independent controls segment held a larger share of the market in 2020 whereas the same is anticipated to register the highest CAGR in the market during the forecast period.
Based on analyte type, the Europe molecular quality controls market has been segmented into single analyte controls and multi-analyte controls. The single analyte controls segment held a larger share of the market in 2020, whereas the multi-analyte control segment is estimated to register the highest CAGR in the market during the forecast period.
The Europe molecular quality control market, by application, is segmented into, infectious diseases, oncology, genetic testing, and other applications. The infectious diseases segment held the largest share of the market in 2020, whereas the oncology segment is anticipated to register the highest CAGR in the market during the forecast period.
Based on end user, the Europe molecular quality control market is segmented into clinical laboratories, hospitals, IVD manufacturers & contract research organizations, academic & research institutes, and other end users. The clinical laboratories segment held the largest share of the market in 2020 and is estimated to register the highest CAGR in the market during the forecast period.
Our reports have been used by over 10K customers, including:
The frozen tissues samples market is projected to reach US$ 105,045.91 Thousand by 2028 from US$ 44,399.07 Thousand in 2021; it is estimated to grow at a CAGR of 13.1% during 2021-2028. The report highlights trends prevailing in the market and the factors driving it.The growth of the frozen tissues samples market is attributed to the...
The anatomic pathology market is projected to reach US$ 33,145.78 million by 2028 from US$ 21,488. 41 million in 2021; it is estimated to grow at a CAGR of 6.4% from 2021 to 2028. Factors such as increase in the prevalence of cancer and other diseases, and growing focus on personalized medicines. However, the lack of skilled professionals...
The anatomic pathology market is projected to reach USD 49.1 billion by 2026 from USD 35.1 billion in 2021, at a CAGR of 7.0%. The growth of the anatomic pathology market is majorly driven by the high incidence of cancer and other target diseases, recommendations for cancer screening, availability of reimbursement, and the growing focus on...
The human microbiome market is expected to reach US$ 2,921.68 million by 2028 from US$ 718.95 million in 2021; it is estimated to grow at a CAGR of 22.2% during 2021-2028. The market growth is mainly attributed to factors such as the increasing incidence of lifestyle diseases, rising focus on human microbiome therapies, and growing...
269 pages •
By The Business Research Company
• Aug 2021
Anatomic Pathology Equipment and Consumables Market Opportunities And Strategies To 2030: COVID-19 Growth And Change provides the strategists, marketers and senior management with the critical information they need to assess the global anatomic pathology equipment and consumables market as it emerges from the COVID 19 shut down. Description: Where...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The Europe organoids market is projected to reach US$ 1,260.08 million by 2027 from US$ 247.85 million in 2019; it is estimated to grow at a CAGR of 22.5% from 2020 to 2027. Increasing demand for tumor modelling and biobanking and rising adoption of personalized drugs are expected to drive the market. Personalized medicine is a growing...
The Middle East & Africa organoids market is expected to reach US$ 141.26 million in 2027 from US$ 37.34 million in 2019; the market is estimated to grow at a CAGR of 20.9% from 2020 to 2027. The growth of the market can be attributed to growing research on organoids in the Middle East & Africa region and rising focus on developing alternatives...
The North America organoids market is expected to reach US$ 1,406.47 million by 2027 from US$ 291.39 million in 2019. The market is anticipated to grow at a CAGR of 21.7% from 2020 to 2027. Growth of the North America organoids market is attributed to emergence of three-dimensional (3D) organoids and rise in investments in research. However,...
The South and Central America nurse call systems market is expected to reach US$ 200.11 million by 2027 from US$ 87.23 million in 2019. The market is estimated to grow at a CAGR of 10.8% from 2020-2027. The growth of the South and Central America nurse call systems market is driven by the growing incidence of Alzheimer’s disease and dementia...
Chronic Disease Prevalence
Practising Nurses And Midwives
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.